Balanced Outlook on Apellis: Near-Term Revenue Uncertainty and Developing Long-Term Upside Justify Hold Rating

Analyst Judah Frommer from Morgan Stanley maintained a Hold rating on Apellis Pharmaceuticals and keeping the price target at $25.00.

Judah Frommer has given his Hold rating due to a combination of factors related to Apellis’s growth profile and execution visibility. He sees near‑term revenue being driven largely by Empaveli’s rollout in C3G and IC‑MPGN, but notes that the rarity of these diseases, diagnostic challenges, and uncertain epidemiology could lead to uneven performance as the opportunity is better defined.

At the same time, he views Syfovre’s outlook as more subdued in the near term, with only modest growth expected as practices recover from prior copay assistance disruptions and new commercial initiatives and long‑term GALE data gradually take hold. Frommer also emphasizes that while management expects cash to fund operations through the path to profitability and the pipeline offers longer‑term upside, these benefits are still developing, warranting a balanced stance rather than a more decisive rating change at this stage.

Frommer covers the Healthcare sector, focusing on stocks such as Galapagos, Incyte, and PTC Therapeutics. According to TipRanks, Frommer has an average return of 0.7% and a 49.81% success rate on recommended stocks.

In another report released today, TipRanks – xAI also reiterated a Hold rating on the stock with a $21.50 price target.